AbbVie Cuts 2024 Profit Forecast Amid Acquisition Costs
AbbVie revises its 2024 profit outlook, citing $1.6 billion in acquisition-related expenses from milestone payments and R&D costs.
AbbVie lowered its 2024 adjusted profit forecast due to $1.6 billion in acquisition expenses related to milestone payments and R&D costs.